Inventor
VALAMEHR BAHRAM
US34 patents
⚠️ This page may combine multiple inventors who share the name “VALAMEHR BAHRAM”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
FATE THERAPEUTICS INC
33 patentsUS10858628B2Dec 8, 2020
Methods and compositions for inducing hematopoietic cell differentiation
FATE THERAPEUTICS INC15 citations93
US10626372B1Apr 21, 2020
Methods and compositions for inducing hematopoietic cell differentiation
FATE THERAPEUTICS INC21 citations93
US11365394B2Jun 21, 2022
Enhanced immune effector cells and use thereof
FATE THERAPEUTICS INC14 citations92
US11072781B2Jul 27, 2021
Genomic engineering of pluripotent cells
FATE THERAPEUTICS INC18 citations92
US10927346B2Feb 23, 2021
Enhanced immune effector cells and use thereof
FATE THERAPEUTICS INC17 citations92
US10287606B2May 14, 2019
Genomic engineering of pluripotent cells
FATE THERAPEUTICS INC28 citations92
US10954529B2Mar 23, 2021
Minimal volume reprogramming of mononuclear cells
FATE THERAPEUTICS INC8 citations84
US10023879B2Jul 17, 2018
Minimal volume reprogramming of mononuclear cells
FATE THERAPEUTICS INC13 citations84
US11162075B2Nov 2, 2021
Methods and compositions for inducing hematopoietic cell differentiation
FATE THERAPEUTICS INC5 citations83
US11162076B2Nov 2, 2021
Methods and compositions for inducing hematopoietic cell differentiation
FATE THERAPEUTICS INC7 citations83
US10947505B2Mar 16, 2021
Methods and compositions for inducing hematopoietic cell differentiation
FATE THERAPEUTICS INC8 citations83
US10844356B2Nov 24, 2020
Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
FATE THERAPEUTICS INC7 citations83
US11634688B2Apr 25, 2023
Methods and compositions for inducing hematopoietic cell differentiation
FATE THERAPEUTICS INC2 citations72
US11352607B2Jun 7, 2022
Genomic engineering of pluripotent cells
FATE THERAPEUTICS INC2 citations71
US11096964B2Aug 24, 2021
Compositions and methods for immune cell modulation in adoptive immunotherapies
FATE THERAPEUTICS INC4 citations71
US11441126B2Sep 13, 2022
Platform for the induction and maintenance of ground state pluripotency
FATE THERAPEUTICS INC2 citations70
US11413309B2Aug 16, 2022
Compositions and methods for immune cell modulation in adoptive immunotherapies
FATE THERAPEUTICS INC4 citations70
US11268069B2Mar 8, 2022
Reprogramming methods and cell culture platforms
FATE THERAPEUTICS INC4 citations70
US12435123B2Oct 7, 2025
Immunotherapies using enhanced iPSC derived effector cells
FATE THERAPEUTICS INC0 citations62
US12410403B2Sep 9, 2025
Methods and compositions for inducing hematopoietic cell differentiation
FATE THERAPEUTICS INC0 citations62
US12385012B2Aug 12, 2025
Methods and compositions for inducing hematopoietic cell differentiation
FATE THERAPEUTICS INC0 citations62
US12264322B2Apr 1, 2025
Minimal volume reprogramming of mononuclear cells
FATE THERAPEUTICS INC0 citations62
US12415989B2Sep 16, 2025
Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
FATE THERAPEUTICS INC0 citations61
US12398373B2Aug 26, 2025
Enhanced immune effector cells and use thereof
FATE THERAPEUTICS INC0 citations61
US12173274B2Dec 24, 2024
Enhanced immune effector cells and use thereof
FATE THERAPEUTICS INC0 citations61
US12281329B2Apr 22, 2025
Compositions and methods for immune cell modulation in adoptive immunotherapies
FATE THERAPEUTICS INC0 citations60
US12275955B2Apr 15, 2025
Combining iPSC derived effector cell types for immunotherapy use
FATE THERAPEUTICS INC0 citations60
US12419870B2Sep 23, 2025
Compositions and methods for immune cell modulation in adoptive immunotherapies
FATE THERAPEUTICS INC0 citations59
US12351831B2Jul 8, 2025
Platform for the induction and maintenance of ground state pluripotency
FATE THERAPEUTICS INC0 citations59
US11851677B2Dec 26, 2023
Composition and methods for inducing myeloid suppressive cells and use thereof
FATE THERAPEUTICS INC0 citations50
US12122846B2Oct 22, 2024
Chimeric antigen receptor for tumor targeting
FATE THERAPEUTICS INC0 citations49
US12247226B2Mar 11, 2025
Cellular reprogramming using temporal and transient plasmid vector expression system
FATE THERAPEUTICS INC0 citations48
US12203098B2Jan 21, 2025
Cells having solid tumor targeting backbone and use thereof
FATE THERAPEUTICS INC0 citations48